Global Hypogonadism Drug Market, By Therapy (Testosterone Replacement Therapy, Gonadotropin, and Gonadotropin-Releasing Hormones Therapy), Drug Delivery (Topical Gels, Injectable, Transdermal Patches, Others), Type (Hypergonadotropic Hypogonadism and Hypogonadotropic Hypogonadism), Mechanism of Action Type (Steroidal Androgens &Gonadotropins), Route of Administration (Oral, Injectable, Tropical), End-Users (Hospitals, Homecare, Specialty Clinics, Others) – Industry Trends and Forecast to 2030.
Hypogonadism Drug Market Analysis and Size
As per a report published by the National Institute of Health (NIH) in 2019, obesity is growing worldwide, and the incidence of hypogonadism is considerably higher in males with obesity as it increases the levels of leptin, insulin, proinflammatory cytokines which are the causative factors for hypogonadism. Several industry companies are increasingly developing drugs for hormonal replacement therapy with higher safety profiles and novel drug delivery mechanisms. Over the forecast period, in the treatment type segment, testosterone replacement therapy is anticipated to witness healthy growth in the upcoming years.
Data Bridge Market Research analyses that the hypogonadism drug market, which was USD 9.13 billion in 2022, would rise up to USD 12.5 billion by 2030 and is expected to undergo a CAGR of 4% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hypogonadism Drug Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015 - 2020) |
|
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
|
Segments Covered |
Therapy (Testosterone Replacement Therapy, Gonadotropin and Gonadotropin-Releasing Hormones Therapy), Drug Delivery (Topical Gels, Injectable, Transdermal Patches, Others), Type (Hypergonadotropic Hypogonadism and Hypogonadotropic Hypogonadism), Mechanism of Action Type (Steroidal Androgens &Gonadotropins), Route of Administration (Oral, Injectable, Tropical), End-Users (Hospitals, Homecare, Specialty Clinics, Others) |
|
Countries Covered |
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
AbbVie Inc. (U.S.), Bausch Health Companies Inc. (Canada), Sun Pharmaceuticals Industries Ltd. (India), Hikma Pharmaceuticals PLC (Japan), Amneal Pharmaceuticals LLC. (U.S.), Alvogen (U.S), Teva Pharmaceutical Industries Ltd (Israel), Endo Pharmaceuticals plc (Ireland), Perrigo Company plc (U.S.), Johnson & Johnson Services, Inc (U.S.), Ferring B.V. (Switzerland), Antares Pharma (US.), Aytu BioPharma, Inc. (U.S.), HYUNDAIPHARM. Co., Ltd (South Korea) |
|
Market Opportunities |
|
Market Definition
Hypogonadism is a hormonal disorder wherein the glands (gonads and ovaries) produce very few hormones causing its deficiency in the body. This hormone is important for the functioning of different sexual characteristics. The individual suffering from hypogonadism may experience loss of libido, weakness, infertility, and osteoporosis. Menopause is the most prevalent cause of hypogonadism. It is normal in all women and occurs on average around age 50.
Global Hypogonadism Drug Market Dynamics
Drivers
- Increasing Prevalence of Postmenopausal Disorders
The growing incidence of postmenopausal disorders can lead to a higher incidence of hypogonadism, increasing market growth. For instance, in 2021, as per the United Nations Economic and Social Commission for Asia-Pacific, a Thailand-based regional commission, over half of the people above 65 years are women, resulting in more than 9% of the total population. By 2050, this percentage of elderly women people is expected to double approximately to more than 18%. This increasing prevalence of postmenopausal disorders leads to a higher demand for hypogonadism drugs as it decreases the levels of testosterone levels. This factor leads to the growth of the market.
- Increasing Government Initiatives
Numerous government initiatives and product approvals are increasing market growth. For instance, Clarus Therapeutics received FDA approval for Jatenzo testosterone, an oral testosterone replacement therapy used for treating primary hypogonadism and hypogonadotropic hypogonadism in men in 2019. In addition to this, Antares Pharma received FDA approval for Xyosted (testosterone enanthate) Injection in 2018. Thus, this factor help in the market growth.
Opportunities
- Increasing Regulations by FDA for Hypogonadism
Several organizations have been increasing regulations that lead to market growth. For instance, the FDA's Department Of Health and Human Services has revised the requirements for particular hormone-containing drug products for human use. These hormones involve estrogens, adrenal corticosteroids, androgens, progestins, anabolic steroids, and synthetic analogs. The aim of revisiting existing regulations by the FDA is to teach the effectiveness and assure safety for any over-the-counter drug use of these ingredients. Thus, this factor boosts market growth.
- Increasing Prevalence of Hypogonadism
As per a report published by the National Institute of Health (NIH) in 2019, obesity is growing worldwide, and the incidence of hypogonadism is considerably greater in males with obesity. In addition, men between 60-80 years generally have low testosterone levels by 20% and 80% compared to normal testosterone levels in young men. Men aged above 60 years have the highest incidence of hypogonadism. Thus, this factor serves as a major factor that increases market growth.
Restraints/Challenges
- Side-Effects of Hypogonadism drug
Numerous effects are associated with hypogonadism drug products. Local effects such as irregular heartbeat, breast swelling, vagina dryness, osteoporosis (weakening of bones), and other effects when women undergo hormone replacement therapy. Thus, this factor impedes market growth.
This hypogonadism drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hypogonadism drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Hypogonadism Drug Market Scope
The hypogonadism drug market is segmented on the basis of therapy, drug delivery, type, mechanism of action type, and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Therapy
- Testosterone Replacement Therapy
- Gonadotropin
- Gonadotropin-Releasing Hormones Therapy
Drug Delivery
- Topical Gels
- Injectable
- Transdermal Patches
- Others
Type
- Hypergonadotropic Hypogonadism
- Hypogonadotropic Hypogonadism
Mechanism of Action Type
- Steroidal Androgens
- Gonadotropins
Route of Administration
- Oral
- Injectable
- Tropical
End-User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Hypogonadism Drug Market Regional Analysis/Insights
The hypogonadism drug market is analyzed and market size insights and trends are provided by therapy, drug delivery, type, mechanism of action type, and end users as referenced above.
The countries covered in the hypogonadism drug market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to grow during the forecast period in the hypogonadism drug market because of the growing cases of hypogonadism with increasing awareness about the hormonal disorder. Additionally, the increase in the patient population is further expected to boost the growth of the hypogonadism drug market in the region in the upcoming years.
North America dominates the market in the forecast period because of the increased adoption of better, highly advanced products. Additionally, the growing consciousness associated with the hormonal disorder containing numerous treatment options and the progressing healthcare infrastructure will further enhance the growth of the hypogonadism drug market in the region during the forecast period.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The hypogonadism drug market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for hypogonadism drug market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the hypogonadism drug market. The data is available for historic period 2011-2021.
Competitive Landscape and Hypogonadism Drug Market Share Analysis
The hypogonadism drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hypogonadism drug market.
Some of the major players operating in the hypogonadism drug market are:
- AbbVie Inc. (U.S.)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceuticals Industries Ltd. (India)
- Hikma Pharmaceuticals PLC (Japan)
- Amneal Pharmaceuticals LLC. (U.S.)
- Alvogen (U.S)
- Teva Pharmaceutical Industries Ltd (Israel)
- Endo Pharmaceuticals plc (Ireland)
- Perrigo Company plc (U.S.)
- Johnson & Johnson Services, Inc (U.S.)
- Ferring B.V. (Switzerland)
- Antares Pharma (U.S.)
- Aytu BioPharma, Inc. (U.S.)
- HYUNDAIPHARM. Co., Ltd (South Korea)
SKU-
